Growth factor supplemented matrigel improves ectopic skeletal muscle formation--a cell therapy approach.
Following damage to skeletal muscle, satellite cells become activated, migrate towards the injured area, proliferate, and fuse with each other to form myotubes which finally mature into myofibers. We tested a new approach to muscle regeneration by incorporating myoblasts, with or without the exogenous growth factors bFGF or HGF, into three-dimensional gels of reconstituted basement membrane (matrigel). In vitro, bFGF and HGF induced C2C12 myoblast proliferation and migration and were synergistic when used together. In vivo, C2C12 or primary i28 myoblasts were injected subcutaneously together with matrigel and growth factors in the flanks of nude mice. The inclusion of either bFGF or HGF increased the vascularization of the gels. Gels supplemented with bFGF showed myogenesis accompanied by massive mesenchymal cell recruitment and poor organization of the fascicles. Samples containing HGF showed delayed differentiation with respect to controls or bFGF, with increased myoblast proliferation and a significantly higher numbers of cells in myotubes at later time points. HGF samples showed limited mesenchymal cell infiltration and relatively good organization of fascicles. The use of both bFGF and HGF together showed increased numbers of nuclei in myotubes, but with bFGF-mediated fibroblast recruitment dominating. These studies suggest that an appropriate combination of basement membrane components and growth factors could represent a possible approach to enhance survival dispersion, proliferation, and differentiation of myogenic cells during muscle regeneration and/or myoblast transplantation. This model will help develop cell therapy of muscle diseases and open the future to gene therapy approaches.
Barbero
A
A
Tumor Progression Section, Istituto Nazionale per la Ricerca sul Cancro, c/o Centro di Biotecnologie Avanzate, Largo Rosanna Benzi 10, 16132, Genova, Italy.
Benelli
R
R
Minghelli
S
S
Tosetti
F
F
Dorcaratto
A
A
Ponzetto
C
C
Wernig
A
A
Cullen
M J
MJ
Albini
A
A
Noonan
D M
DM
D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D017690:Cell Transplantation; D002633:Chemotaxis / Q000187:drug effects; D003094:Collagen; D004338:Drug Combinations; D005109:Extracellular Matrix; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D007797:Laminin; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D018482:Muscle, Skeletal / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D011509:Proteoglycans; D011994:Recombinant Proteins / Q000494:pharmacology; D012038:Regeneration / Q000502:physiology*
D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; C059485:matrigel; D017228:Hepatocyte Growth Factor; D003094:Collagen